{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T07:52:50Z","timestamp":1740124370702,"version":"3.37.3"},"reference-count":13,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2018,7,12]],"date-time":"2018-07-12T00:00:00Z","timestamp":1531353600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2018,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Patients with relapsed\/refractory multiple myeloma (<jats:styled-content style=\"fixed-case\">RRMM<\/jats:styled-content>) have poor prognosis. Pomalidomide is an immunomodulatory compound that has demonstrated activity in <jats:styled-content style=\"fixed-case\">MM<\/jats:styled-content> patients with disease refractory to lenalidomide and bortezomib.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objectives<\/jats:title><jats:p>Participants of clinical trials are highly selected populations; therefore, the aim of this study was to present observations from real practice that might provide important information for practitioners.<\/jats:p><\/jats:sec><jats:sec><jats:title>Patients and Methods<\/jats:title><jats:p>We analyzed retrospectively 50 patients treated with pomalidomide in 12 Polish sites between 2014 and 2017. Median age was 63\u00a0years, median time since diagnosis 4.5\u00a0years and median number of prior regimens 4.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The overall response rate was 39.1%. Median progression\u2010free survival (<jats:styled-content style=\"fixed-case\">PFS<\/jats:styled-content>) and overall survival (<jats:styled-content style=\"fixed-case\">OS<\/jats:styled-content>) were 10.0 and 14.0\u00a0months, respectively. Previous treatment with immunomodulatory drugs, bortezomib or stem cell transplant had no impact on <jats:styled-content style=\"fixed-case\">PFS<\/jats:styled-content> and <jats:styled-content style=\"fixed-case\">OS<\/jats:styled-content>. Most frequent grade 3\/4 treatment\u2010emergent adverse events were hematologic (neutropenia 24.0%, thrombocytopenia 10.0%, anemia 8.0%). Most common grade 3\/4 non\u2010hematologic toxicities were respiratory tract infection (14.0%) and neuropathy (4.0%).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>This real\u2010world data have confirmed that pomalidomide is an active drug in <jats:styled-content style=\"fixed-case\">RRMM<\/jats:styled-content> and support results of published clinical trials and other real\u2010world studies.<\/jats:p><\/jats:sec>","DOI":"10.1111\/ejh.13106","type":"journal-article","created":{"date-parts":[[2018,6,8]],"date-time":"2018-06-08T11:33:53Z","timestamp":1528457633000},"page":"354-361","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["The efficacy and safety of pomalidomide in relapsed\/refractory multiple myeloma in a \u201creal\u2010world\u201d study: Polish Myeloma Group experience"],"prefix":"10.1111","volume":"101","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0595-5864","authenticated-orcid":false,"given":"Grzegorz","family":"Charlinski","sequence":"first","affiliation":[{"name":"Department of Hematology Nicolaus Copernicus Hospital  Torun Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norbert","family":"Grzasko","sequence":"additional","affiliation":[{"name":"Department of Hematology St. John's Cancer Center  Lublin Poland"},{"name":"Department of Experimental Hematooncology Medical University of Lublin  Lublin Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Artur","family":"Jurczyszyn","sequence":"additional","affiliation":[{"name":"Department of Hematology Jagiellonian University Medical College  Krakow Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariusz","family":"Janczarski","sequence":"additional","affiliation":[{"name":"Department of Oncology and Hematology Central Clinical Hospital of the Ministry of Interior and Administration  Warsaw Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agnieszka","family":"Szeremet","sequence":"additional","affiliation":[{"name":"Department of Hematology, Blood Neoplasms and Bone Marrow Transplantation Medical University  Wroclaw Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5626-1750","authenticated-orcid":false,"given":"Anna","family":"Waszczuk\u2010Gajda","sequence":"additional","affiliation":[{"name":"Department of Hematology, Oncology and Internal Diseases Medical University of Warsaw  Warsaw Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pawe\u0142","family":"Bernatowicz","sequence":"additional","affiliation":[{"name":"Department of Hematology Medical University of Bialystok  Bialystok Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alina","family":"Swiderska","sequence":"additional","affiliation":[{"name":"Clinical Department of Hematology University Hospital  Zielona Gora Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renata","family":"Guzicka\u2010Kazimierczak","sequence":"additional","affiliation":[{"name":"Department of Hematology Pomeranian Medical University  Szczecin Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ewa","family":"Lech\u2010Maranda","sequence":"additional","affiliation":[{"name":"Department of Hematology Institute of Hematology and Transfusion Medicine  Warsaw Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrzej","family":"Szczepaniak","sequence":"additional","affiliation":[{"name":"Department of Hematology and Bone Marrow Transplantation University of Medical Sciences  Poznan Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryszard","family":"Wichary","sequence":"additional","affiliation":[{"name":"Department of Hematology and Bone Marrow Transplantation Medical University of Silesia  Katowice Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Dmoszynska","sequence":"additional","affiliation":[{"name":"Polish Myeloma Group  Lublin Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2018,7,12]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-10-078022"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-10-116129"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2011.196"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2009.236"},{"key":"e_1_2_8_6_1","doi-asserted-by":"crossref","first-page":"60656","DOI":"10.18632\/oncotarget.19269","article-title":"Emerging drugs and combinations to treat multiple myeloma","volume":"36","author":"Larocca A","year":"2017","journal-title":"Oncotarget"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70380-2"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa070594"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404284"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-631200"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.47.7901"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14547"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2016.1198957"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2017.1387911"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fejh.13106","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.13106","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,17]],"date-time":"2023-09-17T16:04:06Z","timestamp":1694966646000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ejh.13106"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,12]]},"references-count":13,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["10.1111\/ejh.13106"],"URL":"https:\/\/doi.org\/10.1111\/ejh.13106","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"type":"print","value":"0902-4441"},{"type":"electronic","value":"1600-0609"}],"subject":[],"published":{"date-parts":[[2018,7,12]]},"assertion":[{"value":"2018-05-22","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-07-12","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}